Edition:
United Kingdom

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

86.84EUR
4:36pm GMT
Change (% chg)

€-1.78 (-2.01%)
Prev Close
€88.62
Open
€88.10
Day's High
€89.02
Day's Low
€85.32
Volume
548,901
Avg. Vol
453,480
52-wk High
€105.35
52-wk Low
€70.64

Latest Key Developments (Source: Significant Developments)

Galapagos 9-Month Revenue Rises To 205.1 Million Euros
Wednesday, 24 Oct 2018 

Oct 25 (Reuters) - GALAPAGOS ::REPORTED ON WEDNESDAY 9-MONTH GROUP REVENUES INCREASED BY EUR 98.7 MILLION TO EUR 205.1 MILLION.9-MONTH OPERATING LOSS DECREASED BY EUR 9.1 MILLION TO EUR 53.5 MILLION.9-MONTH NET LOSS DECREASED BY EUR 41.7 MILLION TO EUR 44.2 MILLION.CASH AND CASH EQUIVALENTS ON 30 SEPT 2018 OF EUR1,343.7 MILLION.IN Q4, EXPECTS TO PRESENT MORE DETAILED FINDINGS FROM THE EQUATOR, TORTUGA, AND FINCH 2 TRIALS WITH FILGOTINIB.WILL ALSO PRESENT FIRST DATA AND DEVELOPMENT STRATEGY WITH REGARD TO TOLEDO, OUR NEW PROGRAM IN INFLAMMATORY INDICATIONS.EXPECT TO START DOSING IN THE ISABELA (PH3 IPF `1690) AND PINTA (PH2 IPF `1205) PATIENT TRIALS.DUE TO REVISION OF THE ABBVIE COLLABORATION AGREEMENT IN CF, CO IS REDUCING EXPECTED OPERATIONAL CASH BURN FROM THE LAST GUIDED EUR180-200 MILLION TO EUR140-160 MILLION IN 2018.  Full Article

Galapagos Announces Positive Trial Results With Filgotinib In Psoriatic Arthritis And Ankylosing Spondylitis
Monday, 22 Oct 2018 

Oct 22 (Reuters) - GALAPAGOS NV ::REG-POSITIVE TRIAL RESULTS WITH FILGOTINIB IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS BOTH PUBLISHED IN THE LANCET.RESULTS OF EQUATOR AND TORTUGA STUDIES DEMONSTRATE THAT FILGOTINIB IMPROVED SIGNS AND SYMPTOMS OF PATIENTS WITH PSORIATIC ARTHRITIS.RESULTS OF EQUATOR AND TORTUGA STUDIES DEMONSTRATE THAT FILGOTINIB IMPROVED SIGNS AND SYMPTOMS OF PATIENTS WITH ANKYLOSING SPONDYLITIS.  Full Article

Galapagos: Capital Increase Of EUR 2.0 Million
Wednesday, 3 Oct 2018 

Oct 4(Reuters) - GALAPAGOS ::ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE THROUGH WARRANT EXERCISES.ISSUED 135,485 NEW ORDINARY SHARES ON 3 OCTOBER 2018, FOR A TOTAL CAPITAL INCREASE (INCLUDING ISSUANCE PREMIUM) OF EUR 2,013,590.25.  Full Article

Gilead & Galapagos Announce Filgotinib Meets Primary Endpoint In First Phase 3 Study In Rheumatoid Arthritis
Tuesday, 11 Sep 2018 

Sept 11 (Reuters) - Galapagos NV ::GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN FIRST PHASE 3 STUDY IN RHEUMATOID ARTHRITIS.GALAPAGOS NV - BOTH FILGOTINIB DOSES ALSO ACHIEVED ALL KEY SECONDARY EFFICACY ENDPOINTS.GALAPAGOS NV - TOLERABILITY OF FILGOTINIB WAS CONSISTENT WITH PREVIOUSLY REPORTED STUDIES.GALAPAGOS - FILGOTINIB WAS GENERALLY WELL-TOLERATED IN FINCH 2 TRIAL, WITH NO NEW SAFETY SIGNALS VERSUS THOSE REPORTED IN PREVIOUS TRIALS OF FILGOTINIB.  Full Article

Galapagos NV reports H1 Group Revenues Of €101.9 Million
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Galapagos Nv ::H1 GROUP REVENUES OF €101.9 MILLION.H1 OPERATING LOSS OF €65.8 MILLION.H1 NET LOSS OF €59.1 MILLION.CASH AND CASH EQUIVALENTS ON 30 JUNE 2018 OF €1,066.8 MILLION.DUE TO COLLABORATION WITH NOVARTIS, CO CUTS EXPECTATIONS FOR OPERATIONAL CASH BURN FROM ORIGINALLY GUIDED €220-240 MILLION TO €180-200 MILLION IN 2018.  Full Article

Morphosys And Galapagos Sign Global License Agreement For Mor106 With Pharma Partner
Thursday, 19 Jul 2018 

July 19 (Reuters) - GALAPAGOS NV ::REG-MORPHOSYS AND GALAPAGOS SIGN GLOBAL LICENSE AGREEMENT FOR MOR106 WITH TOP PHARMA PARTNER.EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH NOVARTIS ON MOR106.UP-FRONT PAYMENT OF EUR 95 MILLION (USD 111 MILLION*) AND POTENTIAL MILESTONE PAYMENTS OF UP TO APPROXIMATELY EUR 850 MILLION (USD 1 BILLION*).NOVARTIS TO BEAR ALL FUTURE RESEARCH, DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION COSTS.AGREEMENT BETWEEN MORPHOSYS, GALAPAGOS, AND NOVARTIS IS SUBJECT TO CLEARANCE BY US ANTITRUST AUTHORITIES UNDER HART-SCOTT-RODINO ACT.ROYALTIES UP TO LOW-TEENS TO LOW-TWENTIES.  Full Article

Galapagos Increases Share Capital Through Warrant Exercises
Wednesday, 20 Jun 2018 

June 20(Reuters) - GALAPAGOS NV ::ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE ARISING FROM WARRANT EXERCISES.ISSUED 102,801 NEW ORDINARY SHARES, FOR A TOTAL CAPITAL INCREASE OF EUR 1.3 MLN.EXECUTIVE COMMITTEE MEMBERS COMMITTED TO EXERCISE MINIMUM NUMBER OF WARRANTS.CEO ONNO VAN DE STOLPE EXERCISED 15,000 WARRANTS.THREE OTHER EXECUTIVE COMMITTEE MEMBERS EXERCISED AGGREGATE NUMBER OF 45,000 WARRANTS.  Full Article

Gilead, Galapagos Announce Results With Filgotinib In Phase 2 EQUATOR Study In Psoriatic Arthritis
Wednesday, 30 May 2018 

May 30 (Reuters) - Galapagos NV : :GILEAD AND GALAPAGOS ANNOUNCE RESULTS WITH FILGOTINIB IN THE PHASE 2 EQUATOR STUDY IN PSORIATIC ARTHRITIS AND PROGRESSION INTO PHASE 3 FOR THE SELECTION STUDY IN ULCERATIVE COLITIS.GALAPAGOS NV - EQUATOR ACHIEVES PRIMARY ENDPOINT OF ACR20 RESPONSE AT WEEK 16.GALAPAGOS - CO TO GET $15 MILLION PAYMENT FROM GILEAD FOR PROGRESSION INTO PHASE 3 OF PHASE 2B/3 SELECTION STUDY OF FILGOTINIB IN ULCERATIVE COLITIS.GALAPAGOS NV - FILGOTINIB WAS GENERALLY WELL-TOLERATED IN EQUATOR TRIAL, WITH NO NEW SAFETY SIGNALS OBSERVED.GALAPAGOS NV - THERE WAS ONE SERIOUS INFECTION IN FILGOTINIB GROUP, A PATIENT WHO EXPERIENCED PNEUMONIA WITH A FATAL OUTCOME IN TRIAL.GALAPAGOS NV - IN TRIAL ONE OTHER PATIENT RECEIVING FILGOTINIB DEVELOPED HERPES ZOSTER.GALAPAGOS NV - THERE WERE NO CASES OF OPPORTUNISTIC INFECTION, TUBERCULOSIS, THROMBOEMBOLISM, OR MALIGNANCY IN TRIAL.  Full Article

ProQR And Galapagos Announce Research Collaboration
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Galapagos Nv ::PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY.PROQR THERAPEUTICS - UNDER AGREEMENT, TWO COMPANIES WILL WORK TOGETHER TO DISCOVER NOVEL AXIOMER EONS AGAINST FIBROSIS TARGETS SELECTED BY GALAPAGOS.PROQR THERAPEUTICS NV- TARGETS THAT WILL BE PURSUED IN COLLABORATION AND FINANCIAL DETAILS ABOUT COLLABORATION ARE NOT DISCLOSED.  Full Article

Galapagos NV reports Q3 loss of ‍1.75​ euro per share
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Galapagos NV -:Galapagos NV qtrly ‍revenues 106.4 million euro versus 65 million euro​.Galapagos NV qtrly loss per share ‍1.75​ euro.Galapagos NV says ‍we anticipate cash burn for full year to be at lower end of guidance of euro 135 million - 155 million​.  Full Article

BRIEF-Galapagos Reports Top-line Interim Results Of FALCON Trial Part 1 In CF

* REPORTED ON WEDNESDAY TOPLINE INTERIM RESULTS OF FALCON TRIAL PART 1 IN CF